SCHEMBL1270290

SCHEMBL1270290

CC(C)(C)OC(=O)NC1CC(=O)c2ccccc2NC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 1/20 0.51
▸ GAA P10253 1/20 0.47
▸ CCKAR P32238 2/20 0.46
▸ CCKBR P32239 2/20 0.46
▸ IDO1 P14902 1/20 0.44
▸ BRD4 O60885 3/20 0.43
▸ CREBBP Q92793 3/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ KDM1A O60341 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ PSEN1 P49768 1/20 0.40
▸ PSEN2 P49810 1/20 0.40
▸ APH1B Q8WW43 1/20 0.40
▸ NCSTN Q92542 1/20 0.40
▸ APH1A Q96BI3 1/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ PYGL P06737 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7427232 1.00 EPHX2 (0.51) EPHX2GAACCKARCCKBRIDO1
SCHEMBL29596637 1.00 EPHX2 (0.51) EPHX2GAACCKARCCKBRIDO1
SCHEMBL19228314 1.00 EPHX2 (0.51) EPHX2GAACCKARCCKBRIDO1
SCHEMBL7819751 0.88 EPHX2 (0.46) EPHX2GAACCKARCCKBRIDO1
SCHEMBL9025320 0.86 CCKAR (0.42) EPHX2GAACCKARCCKBRIDO1
SCHEMBL4806148 0.85 EPHX2 (0.63) EPHX2GAACCKARCCKBRIDO1
SCHEMBL651278 0.85 EPHX2 (0.63) EPHX2GAACCKARCCKBRIDO1
SCHEMBL651277 0.85 EPHX2 (0.63) EPHX2GAACCKARCCKBRIDO1
SCHEMBL29900496 0.85 EPHX2 (0.63) EPHX2GAACCKARCCKBRIDO1
SCHEMBL30767473 0.84 GAA (0.44) EPHX2GAAIDO1BRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212891-A1 AZEPINONE DERIVATIVES MSD K.K. 2011-09-01 — — US disclosed
US-7888345-B2 Benzaepinones as sodium channel blockers MERCK SHARP & DOHME CORP. (US) 2011-02-15 — — US disclosed
US-20090181946-A1 Benzaepinones as Sodium Channel Blockers MERCK SHARP & DOHME CORP. 2009-07-16 — — US disclosed
US-20090181946-A1 Benzaepinones as Sodium Channel Blockers MERCK SHARP & DOHME CORP. 2009-07-16 — — US disclosed
EP-0730581-B1 3-ACYLAMINOBENZAZEPINES MERCK & CO INC (US) 2001-10-04 — — EP disclosed
US-5696111-A ANTIARRHYTHMIC AGENTS MERCK & CO., INC. (US) 1997-12-09 — — US disclosed
US-5620972-A Substituted benzene derivatives MERCK SHARP & DOHME LTD. (GB) 1997-04-15 — — US disclosed
EP-0730581-A4 3-ACYLAMINOBENZAZEPINES MERCK & CO INC (US) 1997-02-05 — — EP disclosed
EP-0730581-A1 3-ACYLAMINOBENZAZEPINES MERCK & CO. INC. (US) 1996-09-11 — — EP disclosed
EP-0513974-B1 Novel benzo-fused lactams that promote the release of growth hormone MERCK & CO INC (US) 1996-09-04 — — EP disclosed
EP-0513974-A1 Novel benzo-fused lactams that promote the release of growth hormone MERCK & CO. INC. (US) 1992-11-19 — — EP disclosed
WO-1992016524-A1 BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1992-10-01 — — WO disclosed
EP-0119954-B1 3-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE CIBA-GEIGY AG (CH) 1990-03-14 — — EP disclosed
EP-0119955-B1 3-(5-AMINOPENTYL)-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE CIBA-GEIGY AG (CH) 1989-12-13 — — EP disclosed
US-4575503-A ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1986-03-11 — — US disclosed
EP-0119954-A2 3-Amino-1-benzazepin-2-one-1-alcanoic acids, process for their preparation, their pharmaceutical preparation as well as their therapeutic use CIBA-GEIGY AG (CH) 1984-09-26 — — EP disclosed
EP-0119955-A2 3-(5-Aminopentyl)-amino-1-benzazepin-2-one-1-alcanoic acids, process for their preparation, their pharmaceutical preparation as well as their therapeutic use CIBA-GEIGY AG (CH) 1984-09-26 — — EP disclosed
US-4473575-A ANGIOTENSIN INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1984-09-25 — — US disclosed
US-4410520-A ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1983-10-18 — — US disclosed
EP-0072352-A1 Benzazepin-2-ones, process for their preparation, pharmaceutical preparations containing these compounds and the compounds for therapeutical use CIBA-GEIGY AG (CH) 1983-02-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181946-A1 Benzaepinones as Sodium Channel Blockers TRPV1, TRPA1, KCNN1 EPHX2 3835/4885GAA 1196/4885CCKAR 387/4885
US-20110212891-A1 AZEPINONE DERIVATIVES AZI2, NDUFS3, RPS4Y1 EPHX2 4508/4885GAA 4378/4885CCKAR 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback